Company Encyclopedia
View More
name
Trevi Therapeutics
TRVI.US
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc.
4.514 T
TRVI.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Trevi Therapeutics Announces Appointment Of David Hastings As Chief Financial Officer

    Trevi Therapeutics Inc :TREVI THERAPEUTICS ANNOUNCES APPOINTMENT OF DAVID HASTINGS AS CHIEF FINANCIAL OFFICERTREVI THERAPEUTICS INC - DAVID HASTINGS TO ASSUME CFO ROLE ON JANUARY 6, 2026

    Reuters·
    US
    TRVI
    -1.68%
    Reuters·
    US
    TRVI
    -1.68%

    David Hastings appointed as CFO at Trevi Therapeutics, Nasdaq: TRVI, to lead financial strategy for growth.

    A skilled CFO from the biotech industry has been appointed to oversee financial strategy and support Trevi Therapeutics, Inc.'s growth phase in New Haven, Conn. The company, listed on Nasdaq as TRVI, specializes in developing the experimental drug Haduvio™. This strategic move was announced on Dec. 4, 2025.

    Unusual Whales·
    US
    TRVI
    -1.68%
    Unusual Whales·
    US
    TRVI
    -1.68%

    Trevi Therapeutics Names David Hastings as Chief Financial Officer

    Trevi Therapeutics Inc. has appointed David Hastings as Chief Financial Officer, effective January 6, 2026. Hastings has over 25 years of experience in financial leadership within the life sciences and biopharmaceutical sectors, having held CFO positions at Arbutus, Unilife, Incyte, and ArQule.

    Reuters·
    US
    TRVI
    -1.68%
    Reuters·
    US
    TRVI
    -1.68%

    Trevi Therapeutics edges higher amid takeover speculation

    Trevi Therapeutics (TRVI) shares rose 1.2% in after-hours trading due to takeover speculation. Traders mentioned a Betaville "uncooked" alert suggesting potential acquisition interest, though the buyer's identity remains unknown.

    MSN·
    US
    TRVI
    -1.68%
    MSN·
    US
    TRVI
    -1.68%

    Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Analysts

    Trevi Therapeutics, Inc. (NASDAQ:TRVI) has received an average rating of "Buy" from ten analysts. One analyst rated it as "sell," seven as "buy," and two as "strong buy." The average twelve-month price target is $21.44. Recent analyst reports include price target adjustments and reiterated "buy" ratings. Institutional investors have also modified their holdings, with significant increases in shares owned. The stock opened at $10.99 on Friday, with a market cap of $1.41 billion.

    Market Beat·
    US
    TRVI
    -1.68%
    Market Beat·
    US
    TRVI
    -1.68%
    © 2025 Longbridge｜Disclaimer